Transient immunosuppression with 15-deoxyspergualin prolongs reporter gene expression and reduces humoral immune response after adenoviral gene transfer

Gene Therapy

Volumn 5, Issue 1, 1998, Pages 85-90

  Cichon, G ^a   Strauss, M ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

15 deoxyspergualin; Adenoviral gene transfer; Human alpha 1 antitrypsin; Immunosuppression; Long term expression

Indexed keywords

15 DEOXYSPERGUALIN; ALPHA 1 ANTITRYPSIN; ANTIBODY; CYCLOSPORIN A; TACROLIMUS;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENE TRANSFER; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE;

ADENOVIRIDAE; ANIMALIA; MAMMALIA;

EID: 0031973899     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300555     Document Type: Article

References (41)

1. Haddada H et al. Gene therapy using adenovirus vectors. Curr Top Microbiol Immunol 1995; 199: 297-306.
2. Kass Eisler A et al. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Therapy 1994; 1: 395-402.
3. Mathias P et al. Multiple adenovirus serotypes use alpha v integrins for infection. J Virol 1994; 68: 6811-6814.
4. Bergelson P et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
5. Yang Y et al. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
6. Yang Y et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-369.
7. Fang B et al. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995; 6: 1039-1044.
8. McCoy RD et al. Pulmonary inflammation induced by incomplete or inactivated adenoviral particles. Hum Gene Ther 1995; 6: 1553-1560.
9. Triparthy SK et al. Immune response to transgene-encoded proteins limits the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med 1996; 2: 545-550.
10. Krasnykh VN et al. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996; 70: 6839-6846
11. Krougliak V et al. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther 1995, 6 1575-1586.
12. Kochanek S et al. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA 1996, 93: 5731-5736.
13. Kumarsingh R et al. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum Mol Genet 1996: 5: 913-921
14. Hardy S et al. Construction of adenovirus vectors through Cre lox recombination. J Virol 1997; 71: 1842-1849.
15. Poller W et al. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Gene Therapy 1996; 3: 521-530.
16. Lee MG et al. The constitutive expression of the immunomodulatory gp19k protein in E1-, E3-adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Therapy 1995; 2: 256-262.
17. Hill A et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375: 411-415.
18. Fruh K et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995; 375: 415-418.
19. Levitskaya J et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685-688.
20. Kolls JK et al. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 489-497.
21. Dematteo RP et al. Prolongation of adenoviral transgene expression in mouse liver by lymphocyte subset depletion. Gene Therapy 1996; 3: 4-12.
22. Guerette B et al. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Hum Gene Ther 1996; 7: 1455-1463.
23. Lochmuller H et al. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (MDX) mice. Gene Therapy 1996; 3: 706-716
24. Kass Eisler A et al. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Therapy 1996; 3: 154-162.
25. Matas AJ et al. Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection. Clin Transplant 1994; 8: 116-119.
26. Nadler SG et al. Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin. Ther Drug Monit 1995; 17: 700-703.
27. Smith TAG et al. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Therapy 1996; 3: 496-512.
28. Davenport M et al. Peripheral blood and intrahepatic subsets of T lymphocyte activation and function in liver allograft rejection and drug-induced tolerance in rats. Transpl Immunol 1996; 4: 126-132.
29. el Mansour A et al. Cyclosporin depresses pancreatic islet expression of antigens for islet cell autoantibodies in nonobese diabetic mice. J Autoimmun 1996; 9: 29-39.
30. Cohen DS et al. Cardiac allograft tolerance induction with limited immunosuppression. J Surg Res 1996; 61: 355-360.
31. Stitz L. Induction of antigen-specific tolerance by cyclosporin A. Eur J Immunol 1992; 22: 1995-2001.
32. Jiang H et al. In vivo and in vitro mechanisms of cardiac allograft acceptance in the rat after short treatment with 15-deoxyspergualin. Transpl Int 1992; 5: 139-144.
33. Tepper MA et al. 15-Deoxyspergualin, a novel immunosuppressive drug: studies of the mechanism of action. Ann NY Acad Sci 1993; 685: 136-147
34. Takano Y et al. In vitro kinetic study of the immunosuppressive effect of deoxymethylspergualin on human peripheral blood mononuclear cells. J Clin Lab Immunol 1991; 34: 163-169.
35. Tepper MA et al. Deoxyspergualin inhibits kappa light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-kappa B activation. J Immunol 1995; 155: 2427-2436.
36. Ho S et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80: S40-S45.
37. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
38. Ridge JP et al. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells (see comments). Science 1996; 271: 1723-1726.
39. Bett AJ et al. DNA sequence of the deletion/insertion in early region 3 of Ad5 d1309. Virus Res 1995; 39: 75-82.
40. Kanegae Y et al. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol 1994; 47: 157-166.
41. O'Connor KL et al. Quantitation of two histochemical markers in the same extract using chemiluminescent substrates. Biotechniques 1994; 17: 50-55.